Rachel Bishop

Rachel Bishop

Auto-generated profile, based on publicly available information

Rachel Bishop

NEI, Ophthalmol Consult Serv Sect, NIH, Bethesda, MD 20892 USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2015 in Investigational New Drugs
Verified
Journal Article
Open access
PDF file
KDKhanh Do
Khanh Do
GSGiovanna Speranza
Giovanna Speranza
LCLun-Ching Chang
Lun-Ching Chang
EPEric C. Polley
Eric C. Polley
RBRachel Bishop
Rachel Bishop
Shivaani KummarShivaani Kummar
Shivaani Kummar
Summary Inhibition of heat shock 90 (Hsp90) molecular chaperones allows targeting of multiple proteins involved in tumorigenesis. We investigated the safety, recommended phase 2 dose (RP2D), and pharmacokinetic and pharmacodynamic profile of onalespib (AT13387), a potent synthetic Hsp90 inhibitor, administered on days 1, 2, 8, 9, 15, and 16 of 28 day cycles (QDx2/week) in a phase I trial. This study followed an accelerated titration design with a starting dose of 20 mg/m2/dose and a standard 3 + 3 dose escalation design for dose level 4 (120 mg/m2/dose) and above. Additional patients were enrolled at the RP2D with mandatory paired tumor biopsies to assess modulation of 210 client proteins using reverse phase protein array analysis. Thirty-one patients were treated; RP2D was established at 160 mg/m2/dose on the QDx2/week schedule. Common toxicities were gastrointestinal, hepatic, and hematologic. Pharmacokinetic profile was linear and plasma levels increased proportionally with dose (T½ ~8 h). No responses were observed; eight patients had stable disease for > 2 cycles with one patient remaining on study for 6 cycles. Target engagement was demonstrated by transcriptional upregulation of Hsp70 and Hsp27 in PBMCs. Statistically significant modulation of client proteins was not achieved in the 9 paired tumor biopsies evaluated; however, hierarchical clustering revealed two subgroups of patients with differential patterns of protein expression. Further combination studies are needed in order to target prospective driver oncoproteins.

16 April 2020 in Canadian Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
AEAllen O. Eghrari
Allen O. Eghrari
MRMarjohn M. Rasooly
Marjohn M. Rasooly
MFMichael J. Fliotsos
Michael J. Fliotsos
JKJessica Kinard
Jessica Kinard
OOObinna Odozor
Obinna Odozor
PFPamela A Frischmeyer-Guerrerio
Pamela A Frischmeyer-Guerrerio
Objective Human genome-wide association studies and animal models suggest a role for TGFB2 in contributing to the corneal thickness phenotype. No specific mutations, however, have been reported in this gene that affect corneal thickness. We sought to determine if haploinsufficiency of TGFB2 in humans associated with Loeys–Dietz syndrome type 4 is associated with corneal thinning. Design Observational cohort study of families with Loeys–Dietz syndrome type 4, caused specifically by TGFB2 mutations, in a tertiary care setting. Participants Three probands with pathogenic mutations in TGFB2 and family members underwent comprehensive ophthalmic examination. Methods Clinical assessment included Scheimpflug imaging, specular microscopy, and slit-lamp biomicroscopy. We measured visual acuity, axial length, refractive error, and central corneal thickness. Results Clinical evaluation of 2 probands identified corneal thinning and cornea guttata, despite a young age and distinct mutations in TGFB2 (c.905G>A, p.Arg302His; c.988C>A, p.Arg330Ser). In the third family, corneal thinning co-segregated with a TGFB2 mutation (c.1103G>A, p.Gly368Glu), although without apparent guttae. Conclusions In this series, participants with TGFB2 mutations associated with Loeys–Dietz syndrome type 4 demonstrated decreased corneal thickness, and in 2 cases with splice site mutations, also demonstrated cornea guttata. The data demonstrate the importance of considering distinct phenotype–genotype correlations within this condition.

1 February 2018 in The Lancet Infectious Diseases
Verified
Journal Article
Open access
BCBenjamin W Coleman
Benjamin W Coleman
ISIrini Sereti
Irini Sereti
RBRachel Bishop
Rachel Bishop
BSBryan R Smith
Bryan R Smith

31 March 2023
Verified
Other
Open access
MMMelinda S. Merchant
Melinda S. Merchant
MWMatthew Wright
Matthew Wright
KBKristin Baird
Kristin Baird
LWLeonard H. Wexler
Leonard H. Wexler
CRCarlos Rodriguez-Galindo
Carlos Rodriguez-Galindo
CMCrystal L. Mackall
Crystal L. Mackall

1 September 2021 in Ophthalmology
Verified
Journal Article
Closed access
MMM. Teresa Magone
M. Teresa Magone
IHIris R. Hartley
Iris R. Hartley
EFEdmond FitzGibbon
Edmond FitzGibbon
RBRachel Bishop
Rachel Bishop
MAMike Arango
Mike Arango
RGRachel I. Gafni
Rachel I. Gafni

31 March 2023
Verified
Other
Open access
MMMelinda S. Merchant
Melinda S. Merchant
MWMatthew Wright
Matthew Wright
KBKristin Baird
Kristin Baird
LWLeonard H. Wexler
Leonard H. Wexler
CRCarlos Rodriguez-Galindo
Carlos Rodriguez-Galindo
CMCrystal L. Mackall
Crystal L. Mackall